Fc N-glycosylation of autoreactive Aβ antibodies as a blood-based biomarker for Alzheimer's disease.
Alzheimer's disease
N-glycosylation
amyloid beta
autoantibodies
biomarker
immunoglobulin G
nAbs-Aβ42
naturally occurring autoantibodies
Journal
Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978
Informations de publication
Date de publication:
01 Jun 2023
01 Jun 2023
Historique:
revised:
22
01
2023
received:
19
10
2022
accepted:
24
01
2023
medline:
1
6
2023
pubmed:
1
6
2023
entrez:
1
6
2023
Statut:
aheadofprint
Résumé
Naturally occurring autoantibodies (nAbs) against the pathologic isoform of amyloid beta (Aβ nAbs-Aβ Deglycosylation of nAbs-Aβ42 had a major impact on Aβ N-glycosylation has been identified as a critical attribute maintaining the beneficial effects of autoreactive Aβ antibodies. These data have consequences for the development of monocloncal Aβ antibodies and may open new avenues for diagnostics.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Protein research Unit Ruhr within Europe
ID : 233-1.08.03.03-031-68079
Organisme : Ernst und Margot Faber-Stiftung
Organisme : Deutsche Forschungsgemeinschaft
ID : SE1885/2-2
Organisme : Deutsche Forschungsgemeinschaft
ID : SE1885/4-1
Organisme : Deutsche Krebshilfe
ID : 70112628
Informations de copyright
© 2023 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
Références
Albus A, Kronimus Y, Neumann S, et al. Effects of a multimerized recombinant autoantibody against amyloid-beta. Neuroscience. 2021;463:355-369.
Finder VH, Glockshuber R. Amyloid-beta aggregation. Neurodegener Dis. 2007;4(1):13-27.
Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med. 2016;8(6):595-608.
Ahmed M, Davis J, Aucoin D, et al. Structural conversion of neurotoxic amyloid-beta(1-42) oligomers to fibrils. Nat Struct Mol Biol. 2010;17(5):561-567.
Sakono M, Zako T. Amyloid oligomers: formation and toxicity of Abeta oligomers. FEBS J. 2010;277(6):1348-1358.
Rygiel K. Novel strategies for Alzheimer's disease treatment: an overview of anti-amyloid beta monoclonal antibodies. Indian J Pharmacol. 2016;48(6):629-636.
Prins ND, Scheltens P. Treating Alzheimer's disease with monoclonal antibodies: current status and outlook for the future. Alzheimer's research & therapy. 2013;5(6):56.
Szabo P, Relkin N, Weksler ME. Natural human antibodies to amyloid beta peptide. Autoimmun Rev. 2008;7(6):415-420.
Szabo P, Mujalli DM, Rotondi ML, et al. Measurement of anti-beta amyloid antibodies in human blood. J Neuroimmunol. 2010;227(1-2):167-174.
Bach JP, Dodel R. Naturally occurring autoantibodies against beta-Amyloid. Adv Exp Med Biol. 2012;750:91-99.
Kronimus Y, Dodel R, Neumann S. A quantitative view on naturally occurring autoantibodies in neurodegenerative diseases. J Neurol Neuromedicine. 2018;3(4):5-11.
Dodel R, Balakrishnan K, Keyvani K, et al. Naturally occurring autoantibodies against beta-amyloid: investigating their role in transgenic animal and in vitro models of Alzheimer's disease. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2011;31(15):5847-5854.
Gold M, Mengel D, Roskam S, Dodel R, Bach JP. Mechanisms of action of naturally occurring antibodies against beta-amyloid on microglia. Journal of Neuroinflammation. 2013;10:5.
Mengel D, Roskam S, Neff F, et al. Naturally occurring autoantibodies interfere with beta-amyloid metabolism and improve cognition in a transgenic mouse model of Alzheimer's disease 24 h after single treatment. Transl Psychiatry. 2013;3:e236.
Anthony RM, Wermeling F, Ravetch JV. Novel roles for the IgG Fc glycan. Ann NY Acad Sci. 2012;1253:170-180.
Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol. 2007;25:21-50.
Tomana M, Schrohenloher RE, Koopman WJ, Alarcon GS, Paul WA. Abnormal glycosylation of serum IgG from patients with chronic inflammatory diseases. Arthritis Rheum. 1988;31(3):333-338.
Decker Y, Schomburg R, Nemeth E, et al. Abnormal galactosylation of immunoglobulin G in cerebrospinal fluid of multiple sclerosis patients. Mult Scler. 2016;22(14):1794-1803.
Richter M, Nickel C, Apel L, et al. SK channel activation modulates mitochondrial respiration and attenuates neuronal HT-22 cell damage induced by H2O2. Neurochem Int. 2015;81:63-75.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939-944.
Goodyear MD, Krleza-Jeric K, Lemmens T. The Declaration of Helsinki. BMJ. 2007;335(7621):624-625.
Feige MJ, Nath S, Catharino SR, Weinfurtner D, Steinbacher S, Buchner J. Structure of the murine unglycosylated IgG1 Fc fragment. J Mol Biol. 2009;391(3):599-608.
Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014;5:520.
Kronimus Y, Dodel R, Galuska SP, Neumann S. IgG Fc N-glycosylation: Alterations in neurologic diseases and potential therapeutic target? J Autoimmun. 2019;96:14-23.
Yamada E, Tsukamoto Y, Sasaki R, Yagyu K, Takahashi N. Structural changes of immunoglobulin G oligosaccharides with age in healthy human serum. Glycoconj J. 1997;14(3):401-405.
Abès R, Teillaud JL. Impact of Glycosylation on Effector Functions of Therapeutic IgG. 2010.
Bakovic MP, Selman MH, Hoffmann M, et al. High-throughput IgG Fc N-glycosylation profiling by mass spectrometry of glycopeptides. J Proteome Res. 2013;12(2):821-831.
Wong AH, Fukami Y, Sudo M, Kokubun N, Hamada S, Yuki N. Sialylated IgG-Fc: a novel biomarker of chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry. 2016;87(3):275-279.
van de Bovenkamp FS, Derksen NIL, Ooijevaar-de Heer P, et al. Adaptive antibody diversification through N-linked glycosylation of the immunoglobulin variable region. Proc Natl Acad Sci U S A. 2018;115(8):1901-1906.
Abes R, Teillaud JL. Impact of glycosylation on effector functions of therapeutic IgG. Pharmaceuticals (Basel). 2010;3(1):146-157.
Raju TS. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol. 2008;20(4):471-478.
Selman MH, Niks EH, Titulaer MJ, Verschuuren JJ, Wuhrer M, Deelder AM. IgG fc N-glycosylation changes in Lambert-Eaton myasthenic syndrome and myasthenia gravis. J Proteome Res. 2011;10(1):143-152.
Lundstrom SL, Yang H, Lyutvinskiy Y, et al. Blood plasma IgG Fc glycans are significantly altered in Alzheimer's disease and progressive mild cognitive impairment. J Alzheimers Dis. 2014;38(3):567-579.
Fokkink WJ, Selman MH, Dortland JR, et al. IgG Fc N-glycosylation in Guillain-Barre syndrome treated with immunoglobulins. J Proteome Res. 2014;13(3):1722-1730.
Clendenen TV, Hu S, Afanasyeva Y, et al. Temporal reproducibility of IgG and IgM autoantibodies in serum from healthy women. Sci Rep. 2022;12(1):6192.